A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency
- 1 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (2) , 408-423
Abstract
For anthracycline-based chemotherapy to be immunogenic, dying cancer cells must release annexin A1 (ANXA1) that subsequently interacts with the pattern recognition receptor, formyl peptide receptor 1 (FPR1), on the surface of dendritic cells (DC). Approximately 30% of individuals bear loss-of-function alleles of FPR1, calling for strategies to ameliorate their anticancer immune response. Here, we show that immunotherapy with a ligand of Toll-like receptor-3, polyinosinic:polycytidylic acid (pIC), restores the deficient response to chemotherapy of tumors lacking ANXA1 developing in immunocompetent mice or those of normal cancers growing in FPR1-deficient mice. This effect was accompanied by improved DC- and T-lymphocyte–mediated anticancer immunity. Of note, carcinogen-induced breast cancers precociously developed in FPR1-deficient mice as compared with wild-type controls. A similar tendency for earlier cancer development was found in patients carrying the loss-of-function allele of FPR1. These findings have potential implications for the clinical management of FPR1-deficient patients. Significance: The loss-of-function variant rs867228 in FPR1, harbored by approximately 30% of the world population, is associated with the precocious manifestation of breast, colorectal, esophageal, and head and neck carcinomas. pIC restores deficient chemotherapeutic responses in mice lacking Fpr1, suggesting a personalized strategy for compensating for the FPR1 defect. This article is highlighted in the In This Issue feature, p. 211Keywords
All Related Versions
Funding Information
- Novo Nordisk Fonden (NNF15OC0016584)
- Research and Technology Innovation Fund (KTIA_NAP_13- 2014-0021)
- Research and Technology Innovation Fund (NAP2-2017-1.2.1-NKP-0002)
- Breast Cancer Research Foundation (BCRF-18-159)
- Det Frie Forskningsråd (19#7016-00345B)
- DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs (W81XWH-18-2-0056)
- Ligue Contre le Cancer
- Ruban Rose
- Canceropôle PACA
- Institut Gustave-Roussy (Odyssea)
- Institut National Du Cancer
- Institut National de la Santé et de la Recherche Médicale
- Institut Universitaire de France
- Agence Nationale de la Recherche
- European Commission
- Université Paris Descartes
- HTE heterogeneity of tumoral ecosystem
- Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche
This publication has 38 references indexed in Scilit:
- Generation of Inducible Immortalized Dendritic Cells with Proper Immune Function In Vitro and In VivoPLOS ONE, 2013
- Wogonin Induced Calreticulin/Annexin A1 Exposure Dictates the Immunogenicity of Cancer Cells in a PERK/AKT Dependent MannerPLOS ONE, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Mutations in MTFMT Underlie a Human Disorder of Formylation Causing Impaired Mitochondrial TranslationCell Metabolism, 2011
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor ApoptosisCancer Research, 2011
- Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- TLR4polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humansProceedings of the National Academy of Sciences, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005